Many signaling pathways are found to be involved in the pathogeny of NKTCL, among which, NF‐κB and JAK/STAT are the best studied.26, 27 Studies showed that NF‐κB mutation was related to drug resistance among NKTCL patients.28 From 65 cases of NKTCL patients, Koo et al29 found 23 cases (35.4%) showed JAK3 mutation, indicating that JAK/STAT signaling pathway is involved in the oncogenesis and progression of NKTCL. Here, JAK3 is linked to extranodal nasal NK/T cell lymphoma.